title: Is18F-FDG-PET suitable to predict clinical response to the treatment of geriatric depression? A systematic review of PET studies.
abstract: Geriatric depression is one of the most common psychiatric disorders in later life. It differs from earlier depression in its presentation, etiology, risk factors, protective factors and outcome. Positron emission tomography (PET) can be used to detect changes in neural circuitry in neuropsychiatric disorders, and several authors have assessed its role in the diagnosis and follow-up of patients with geriatric depression. We reviewed the current evidence on the use of fluorine-18-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) in geriatric depressed patients to find predictors of treatment response.
  
  
  
  We searched PubMed/MEDLINE, Scopus, Embase, Cochrane Library, CINAHL and the PsycINFO databases to find relevant peer-reviewed articles on PET in geriatric depression using the search terms ('PET' or 'positron emission tomography') and ('mood' or 'affective disorder' or 'affective disorders' or 'depression' or 'dysthymia' or 'seasonal affective disorder').
  
  
  
  Eleven articles comprising 128 patients were included. We extracted data on glucose uptake of depressed patients and controls at baseline and after different types of intervention (total sleep deprivation followed by a recovery sleep and treatment with selective serotonin reuptake inhibitors).
  
  
  
  18F-FDG-PET showed significant alterations of glucose uptake in several brain areas, in particular the anterior cingulate cortex, which showed reduced metabolism after treatment, and was a predictor of treatment response.
authors: a Department of Psychiatry , Catholic University of Sacred Heart , Rome , Italy.
authors: Franco
authors: F
authors: De Crescenzo
authors: b Department of Radiology , Catholic University of Sacred Heart , Rome , Italy.
authors: Mario
authors: M
authors: Ciliberto
authors: c Department of Neuroscience , Bambino Gesù Children's Hospital , Rome , Italy.
authors: Deny
authors: D
authors: Menghini
authors: d Department of Nuclear Medicine and PET/CT Center , Oncology Institute of Southern Switzerland , Bellinzona , Switzerland.
authors: Giorgio
authors: G
authors: Treglia
authors: e Department of Psychiatry , University of Oxford , Oxford , United Kingdom.
authors: Klaus P
authors: KP
authors: Ebmeier
authors: a Department of Psychiatry , Catholic University of Sacred Heart , Rome , Italy.
authors: Luigi
authors: L
authors: Janiri
mesh_terms: D000368:Aged; D000375:Aging / Q000378:metabolism / Q000502:physiology; D001786:Blood Glucose / Q000378:metabolism; D001921:Brain / Q000000981:diagnostic imaging* / Q000378:metabolism; D016022:Case-Control Studies; D003863:Depression / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000378:metabolism; D019788:Fluorodeoxyglucose F18; D006801:Humans; D017374:Paroxetine / Q000008:administration & dosage; D049268:Positron-Emission Tomography; D012680:Sensitivity and Specificity; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage; D012892:Sleep Deprivation / Q000378:metabolism
chemical_list: D001786:Blood Glucose; D019788:Fluorodeoxyglucose F18; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors
keywords: PET; aging; blood glucose/metabolism; depressive disorder; fluorine-18-fluorodeoxyglucose